Antheia’s Role in Onshoring America’s Critical Medicine Supply
As we head into spring, the urgency around onshoring America’s critical medicine supply chains has never been clearer or better supported.
Reflecting on a Year of Momentum at Antheia

As 2025 comes to a close, there is so much to be proud of at Antheia. We reached major milestones this year, including closing our $56 million Series C, welcoming a new CFO, and forging strategic partnerships to expand our global manufacturing capabilities. Each achievement brings us closer to our mission of transforming pharmaceutical supply chains and ending drug shortages.
Welcome to the first edition of Antheia Insights!

Over the last few years, the Antheia team has made significant progress toward our mission of transforming pharmaceutical supply chains to end shortages of essential medicines. With several industry-first milestones under our belt and many more on…
Synthetic Biology at Scale: Less Disruption, More Cohesion

For synthetic biology companies, scaling up means reaching out—working with government bodies, identifying partners, and securing manufacturing capacity
Antheia Secures $17 Million to Boost U.S. Production of Critical Pharmaceutical Ingredients

Antheia, a pioneering pharmaceutical ingredient manufacturer, has announced a significant $17 million funding boost aimed at transforming the supply chains of essential medicines.
Antheia Announces $17 Million in Funding for Domestic Pharmaceutical Ingredient Production

Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical production sites.
Antheia secures new funding to boost pharmaceutical ingredients production

The company secured funding through government project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), alongside strategic investment from In-Q-Tel and Echo
Secretary of State Antony Blinken visits the Bay Area
Antony Blinken tours Antheia biotech lab, emphasizing its potential to address nationwide medicine shortages by overcoming supply chain issues with advanced bio-technology
Chemicals Knowledge Hub: DCAT Week 2024 Andrea Conforto, VP/Biotech for CDMO at Olon and Zack McGahey, COO at Antheia
In this interview with Antheia and Olon, two leading companies in the life sciences industry, we discussed their ongoing partnership, market trends, and the future of the industry.
PharmaSource: Antheia and Olon Extend Biomanufacturing Partnership
Antheia and Olon have announced a continuation of partnership, leveraging Olon’s fermentation infrastructure for the manufacture of Antheia’s early products